TDOC Stock Chart & Stats
$105.19
-$1.33(-0.86%)
At close: 4:00 PM EDT
$105.19
-$1.33(-0.86%)
Day’s Range― - ―
52-Week Range$78.00 - $176.00
Previous CloseN/A
Volume162.00
Average Volume (3M)130.00
Market Cap
$18.21B
Enterprise Value$1.80B
Total Cash (Recent Filing)$774.35M
Total Debt (Recent Filing)$1.04B
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Oct 28, 2026EPS Estimate
-3.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding181,684,020
10 Day Avg. Volume23
30 Day Avg. Volume130
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.89
Price to Sales (P/S)0.49
P/FCF Ratio4.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$139.23Price Target Upside32.36% Upside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)-15.58
Revenue Forecast (FY)$43.57B
Bulls Say, Bears Say
Bulls Say
Positive Cash Generation And LiquidityTeladoc is generating substantial operating and free cash flow despite reported accounting losses. This internally generated liquidity can fund platform investment, support insurance-transition execution, and reduce reliance on external financing over the next several quarters.
Integrated Care Scale And Margin ExpansionIntegrated Care combines a very large contracted member base with growing chronic-care enrollment and improving profitability. Margin expansion and hybrid-care growth indicate better operating leverage and provide a durable foundation while other segments undergo transition.
Product And Technology InnovationThe unified Teladoc 1 model and Pulse intelligence engine broaden the platform beyond individual virtual visits toward connected, data-enabled care. If adoption develops as planned, these products can deepen customer relationships and support cross-selling across populations.
Bears Say
Persistent Losses And Weak Revenue TrajectoryTeladoc has improved materially from its largest historical losses, but it remains below operating break-even while revenue trends are weak. Without renewed top-line growth, the company may struggle to convert gross margin and cost actions into durable earnings.
BetterHelp Revenue ContractionBetterHelp remains a meaningful drag on consolidated growth as cash-pay revenue declines faster than the insurance model can replace it. The lowered segment outlook reduces near-term revenue scale and raises execution risk around rebuilding sustainable demand.
Provider Capacity Limits Insurance ConversionThe insurance transition depends not only on customer demand but also on sufficient credentialed provider availability across states, payers, and appointment times. Capacity bottlenecks can delay revenue conversion and prolong the period of pressure on BetterHelp.
Teladoc News
TDOC FAQ
What was Teladoc’s price range in the past 12 months?
Teladoc lowest stock price was $78.00 and its highest was $176.00 in the past 12 months.
What is Teladoc’s market cap?
Teladoc’s market cap is $18.21B.
When is Teladoc’s upcoming earnings report date?
Teladoc’s upcoming earnings report date is Oct 28, 2026 which is in 23 days.
How were Teladoc’s earnings last quarter?
Teladoc released its earnings results on Jul 29, 2026. The company reported -$3.814 earnings per share for the quarter, beating the consensus estimate of -$4.54 by $0.726.
Is Teladoc overvalued?
According to Wall Street analysts Teladoc’s price is currently Undervalued.
Does Teladoc pay dividends?
Teladoc does not currently pay dividends.
What is Teladoc’s EPS estimate?
Teladoc’s EPS estimate is -3.94.
How many shares outstanding does Teladoc have?
Teladoc has 181,684,020 shares outstanding.
What happened to Teladoc’s price movement after its last earnings report?
Teladoc reported an EPS of -$3.814 in its last earnings report, beating expectations of -$4.54. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Teladoc?
Currently, no hedge funds are holding shares in MX:TDOC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teladoc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$139.23 (32.36% Upside)
$139.23 (32.36% Upside)
Blogger Sentiment
Bullish
MX:TDOC Sentiment 63%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.68%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Teladoc
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.
TDOC Company Deck
TDOC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but balanced picture: clear strength and margin expansion in Integrated Care, meaningful product and AI-driven innovation (Teladoc 1 and Pulse), strong liquidity and disciplined cost actions. Offsetting these positives were material near-term challenges in BetterHelp as the business transitions from cash-pay to an insurance/in-network model — accelerated declines in cash-pay users, provider capacity constraints that limited insurance conversion, and a downward revision to consolidated revenue guidance. Management has taken decisive actions (national insurance rollout, provider recruitment/activation initiatives, lower ad spend) to address the issues, but execution risk and timing remain. Overall, the results show operational progress in core businesses and constructive steps to fix the BetterHelp transition, balanced by meaningful short-term revenue pressure and uncertainty in that segment.View all MX:TDOC earnings summariesTDOC Revenue Breakdown
56.44% Teladoc Health Integrated Care
43.56% BetterHelp
TDOC Stock 12 Month Forecast
Average Price Target
$139.23
▲(32.36% Upside)